{"id":585028,"date":"2026-06-24T14:17:35","date_gmt":"2026-06-24T14:17:35","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/?p=585028"},"modified":"2026-06-24T14:19:39","modified_gmt":"2026-06-24T14:19:39","slug":"from-complexity-to-clarity-why-patient-centered-communication-matters","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/blog\/from-complexity-to-clarity-why-patient-centered-communication-matters\/","title":{"rendered":"From complexity to clarity: Why patient centered communication matters"},"content":{"rendered":"

Across the pharmaceutical industry, regulatory affairs, market access and clinical care, there is growing recognition that patients should be active partners in decision making, rather than passive recipients of decisions. Pharmaceutical companies are increasingly considering patient input to inform drug development, evidence generation and regulatory decision-making.1, 2, 3<\/sup> In parallel, healthcare systems are encouraging patient engagement to enable shared decision-making,4, 5<\/sup> while patients themselves are becoming more informed, empowered, and vocal about what matters to them.8, 9<\/sup> Meaningful patient involvement helps ensure drug development reflects real world needs, supports informed choices, improves accessibility and outcomes, and builds trust and transparency.<\/p>\n

However, meaningful patient engagement remains challenging when information is highly technical and framed in scientific, clinical, or regulatory language.6,7,10,11<\/sup> This issue underscores the central importance of patient\u2011centred communication. Clear, patient\u2011focused communication materials play a key role in translating complex evidence into accessible, relevant and empathetic language. When thoughtfully designed, these materials enable patients to understand the evidence, build trust in the information presented, and more confidently engage in decisions about their care.<\/p>\n

Drawing on our experience developing evidence-based, patient communication materials, we have outlined six core principles underpinning effective patient\u2011centred communication.<\/p>\n

    \n
  1. \n

    Start with what matters to patients<\/strong><\/h3>\n<\/li>\n<\/ol>\n

    Effective patient\u2011centred communication starts by focusing on what matters most to patients: their daily challenges, the outcomes they value, and their lived experiences of the disease and treatment.<\/p>\n

    What symptoms or side effects worry them most? What interventions are available and what are the benefits and risks associated with treatment? What practical issues shape their day\ufffcto\ufffcday lives? Tailoring communication around these questions makes information more relevant than messaging driven solely by what experts feel compelled to explain.<\/p>\n

    Insights from patient interviews, advocacy groups, surveys, and lived\ufffcexperience research help anchor communication in real patient concerns, shifting the focus from \u201cWhat do we want to say?\u201d to \u201cWhat do patients need to know to feel informed and supported?\u201d<\/p>\n

      \n
    1. \n

      Translate complexity without losing meaning<\/strong><\/h3>\n<\/li>\n<\/ol>\n

      Scientific and regulatory information is often complex, including specialised terminology, dense data, and methodological detail. Interpreting and distilling this complexity into accessible, meaningful insights, without compromising scientific accuracy, is important when creating patient\u2011focused communication materials.<\/p>\n

      In practice, this involves explaining the why behind the science, clarifying what results actually mean for patients, and separating essential messages from unnecessary technical detail. Simplification should be thoughtful rather than reductive, ensuring scientific integrity is maintained. When this balance is achieved, communication retains scientific rigour while delivering insights that are meaningful and relevant to patients.<\/p>\n

        \n
      1. \n

        Write in clear, inclusive, and accessible language<\/strong><\/h3>\n<\/li>\n<\/ol>\n

        Once key messages have been identified and interpreted, how they are expressed becomes equally important. Clear, inclusive language enables understanding across diverse patient populations with varying levels of health literacy, cultural backgrounds, and experiences.<\/p>\n

        Use everyday language wherever possible (for example, \u201cswelling\u201d instead of \u201coedema,\u201d \u201cshortness of breath\u201d instead of \u201cdyspnoea\u201d). Keep sentences short, active, and direct, and avoid jargon, unexplained acronyms or overly formal phrasing.<\/p>\n

        Cultural context also matters. Concepts such as quality of life may be interpreted differently across cultures. Where possible, materials should be tested for readability and comprehension with diverse patient groups to identify unintended barriers.<\/p>\n

          \n
        1. \n

          Be transparent about uncertainty, risk, and evidence<\/strong><\/h3>\n<\/li>\n<\/ol>\n

          Once complexity and language have been addressed, transparency becomes essential. Patients value honesty, particularly when it comes to uncertainty, risk, and evidence limitations.<\/p>\n

          Avoid vague phrasing such as \u201cclinically meaningful improvement\u201d without explanation. Present risks and benefits using natural frequencies (for example, \u201c3 out of 100 people\u201d rather than \u201c3% of people\u201d), be explicit about side effects, acknowledge evidence gaps, and describe variability in response (\u201csome people notice an improvement quickly, while others may take longer\u201d).<\/p>\n

          Transparency builds trust, which can be achieved by setting realistic expectations, reducing misunderstanding, and enabling patients to weigh benefits and risks in line with their own values, ultimately supporting informed decision-making.<\/p>\n

            \n
          1. \n

            Choose the right format, not just the right words<\/strong><\/h3>\n<\/li>\n<\/ol>\n

            Patient-centred communication is not only about wording, but also about presentation. Many patients absorb information more effectively through visuals, step\ufffcby\ufffcstep layouts, FAQs, or layered content than through dense text.<\/p>\n

            Thoughtful design may include infographics to explain timelines, icons or colour coding for navigation, short summaries followed by optional deeper detail, or visual metaphors to explain benefits and risks. In some settings, short videos or animations can further enhance understanding and engagement.<\/p>\n

            Well-designed visual materials reduce cognitive load and help patients engage with, understand, and use information more confidently.<\/p>\n

            Figure 1: Bringing patient-reported outcomes to life through engaging, patient-friendly visuals<\/strong><\/p>\n

            \"\"<\/p>\n

              \n
            1. \n

              Test, refine, and iterate with patients<\/strong><\/h3>\n<\/li>\n<\/ol>\n

              To ensure patient-focused communication materials are truly impactful, they should be informed by direct patient feedback through user testing, advocacy group input, or informal reviews. This process will often highlight gaps or assumptions that internal teams may overlook.<\/p>\n

              Testing helps reveal how patients actually engage with materials in practice. What resonates, what confuses, and what feels overwhelming will differ by audience and format, making testing an essential, context\u2011specific step.<\/p>\n

              Refinement and iteration through real patient input ensures materials are not just well\ufffcintentioned but genuinely support patient understanding and use.<\/p>\n

              Writing with the patient in mind: Key takeaways<\/strong><\/h3>\n

              Patient-centred communication starts with understanding what patients need to know and how they need to hear it. When scientific accuracy is balanced with clarity, inclusivity, transparency, and thoughtful design, complex information becomes more usable, relevant, and meaningful for the audience it is intended to support.<\/p>\n

              Ultimately, writing that puts patients first strengthens engagement, builds trust, and helps patients and healthcare professionals make better informed decisions together.<\/p>\n

              At Clarivate, our Value Communication team have extensive experience delivering clear, coherent, patient-centred tools and resources for patient advocacy groups, including outcome-focused messaging decks, plain language summaries, and patient<\/em>\u2011centricity training materials and workshops. If you would like to learn more about how we can support your patient\ufffcengagement goals, please get in touch <\/em>Healthcare Commercial Consulting Services | Clarivate<\/a><\/p>\n

              This post was written by Ulrike Jahnke, Medical Writer, and Sonia Alesso, Director, Value Communication, LS&H, Clarivate.<\/em><\/p>\n

              References<\/strong><\/h3>\n

              1 FDA. FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient\u2019s Voice in Medical Product Development and Regulatory Decision Making. October 23, 2025. Available at: FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient\u2019s Voice in Medical Product Development and Regulatory Decision Making | FDA<\/a><\/p>\n

              2 EMA. Getting involved in EMA activities as a patient, consumer or carer. April 01, 2026. Available at: Getting involved in EMA activities as a patient, consumer or carer | European Medicines Agency (EMA)<\/a><\/p>\n

              3 EMA. Patient engagement: from a patient centric drug development to authorisation. June 27, 2023. Available at: Evaluation and post-authorisation activities involving patients<\/a><\/p>\n

              4 NICE. Shared decision making. June 17, 2021. Available at: Shared decision making<\/a><\/p>\n

              5 Galletta M, Piazza MF, Meloni SL, Chessa E, Piras I, Arnetz JE, D’Aloja E. Patient Involvement in Shared Decision-Making: Do Patients Rate Physicians and Nurses Differently? Int J Environ Res Public Health. 2022 Oct 31;19(21):14229<\/p>\n

              6 Chamberlain James, L. Plain language summaries of clinical trial results: What is their role, and should patients and AI be involved? EMWA 2024;33(3):34\u201337<\/p>\n

              7 NIHR. Involving patients and members of the public in research. September 2025. Available at: Involving patients and members of the public in research v0.2<\/a><\/p>\n

              8 CDC. Patient Engagement. June 21, 2024. Available at: Patient Engagement | Health Literacy | CDC<\/a><\/p>\n

              9 SmartStory. Patient Engagement Statistics Shaping the Future of Care. April 03, 2025. Available at: 9 Patient Engagement Statistics Shaping the Future of Care<\/a><\/p>\n

              10 Dews SA, Daley R, Bansal A, Preston J, Bohm N. The power of language: how to bridge the gap between healthcare research and patients – a scoping review. Curr Med Res Opin. 2024 Feb;40(2):279-291<\/p>\n

              11 Daniel D, Khaleeluzzama Takidar S, Mackinnon J. Medical writers moving the needle on patient-centred communication and engagement. EMWA 2025;34(2):32\u201338<\/p>\n","protected":false},"excerpt":{"rendered":"

              Across the pharmaceutical industry, regulatory affairs, market access and clinical care, there is growing recognition that patients should be active partners in decision making, rather than passive recipients of decisions….<\/p>\n","protected":false},"author":59,"featured_media":266814,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_links_to":"","_links_to_type":0,"footnotes":""},"categories":[19],"tags":[40,414,2501,118,2611,3005,2619,333,335],"class_list":["post-585028","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","tag-biopharma","tag-biotech","tag-commercialization","tag-digital-health","tag-launch","tag-multichannel-engagement","tag-patient","tag-pharma","tag-point-of-care"],"acf":[],"lang":"en","translations":{"en":585028,"ja":585105,"ko":585106},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/585028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/users\/59"}],"replies":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/comments?post=585028"}],"version-history":[{"count":5,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/585028\/revisions"}],"predecessor-version":[{"id":585109,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/585028\/revisions\/585109"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media\/266814"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=585028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/categories?post=585028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/tags?post=585028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}